GET DAILY SIGNALSWhy Is PDS Biotechnology (PDSB) Stock Up +23.08% Today?
Key Takeaways
- PDS Biotechnology (PDSB) jumped roughly 23% on Wednesday, extending a sharp two-session rally.
- The primary catalyst was the closing of a multi-tranche private financing led by Nant Capital, alongside the appointment of Dr. Patrick Soon-Shiong to the board.
- Investors are reading the financing as a vote of confidence in the company's lead program, PDS0301, an IL-12 immunocytokine in development for metastatic colorectal cancer.
- Elevated trading volume and continued momentum in small-cap biotech added to the upward pressure.
- Traders are now watching for a milestone closing tied to the submission of a Phase 3 protocol to the FDA.
- For deeper data on Price Targets, Earnings, and Forecast, explore Tickeron's dedicated pages for this ticker.
- Curious how AI trading systems are positioning for moves like this? Visit Trending AI Robots.
Opening Summary
PDSB, PDS Biotechnology Corporation, is a clinical-stage immunotherapy company developing targeted cancer treatments, including its lead IL-12 immunocytokine PDS0301 and its HPV16-targeted Versamune platform. The stock surged about 23.08% on Wednesday, trading near $1.60 after closing the prior session at $1.30. The advance marked a decisive upward move driven by news that the company closed a multi-tranche financing led by Nant Capital, a strategic investor associated with entrepreneur and physician Dr. Patrick Soon-Shiong.
Financing and Board Appointment Fuel the Rally
The primary driver behind the move was the closing of a multi-tranche private investment in public equity (PIPE) financing of up to roughly $22.3 million led by Nant Capital. The deal provides much-needed runway for a company that ended recent quarters with a thin cash position and a negative operating cash flow, a common profile among clinical-stage biotechs.
Equally important to investors was the appointment of Dr. Patrick Soon-Shiong to the board of directors. Soon-Shiong's involvement, through Nant Capital and NantWorks, is being interpreted as external validation of PDS Biotechnology's immunotherapy platform. In connection with the transaction, the company also granted NantWorks an exclusive negotiation right on a potential license to PDS0101, its HPV16-targeted candidate.
Clinical Data Provides the Underlying Narrative
Beyond the financing itself, the rally reflects renewed optimism around the company's science. PDS0301, an investigational tumor-targeted IL-12 immunocytokine, has shown encouraging interim Phase 2 results in microsatellite-stable (MSS) metastatic colorectal cancer with liver metastases, a setting where immunotherapy has historically struggled. A small, non-randomized cohort reported an objective response rate of roughly 78% alongside durable survival signals, data that management is using to advance the program toward a registrational Phase 3 trial.
A portion of the financing is structured as a milestone closing contingent on the company submitting a Phase 3 clinical trial protocol for PDS0301 to the FDA. That structure ties new capital directly to the regulatory advancement of the lead program, which traders view as a catalyst that could unlock additional funding and further de-risk the pipeline.
Market Context and Trading Activity
Wednesday's advance came on elevated trading volume, consistent with a news-driven move rather than a passive drift. The previous session also saw volume roughly two to five times recent daily averages, underscoring the intensity of interest in the stock. The move aligned with momentum across speculative, micro-cap biotechnology names, where clinical catalysts and financing events frequently trigger outsized percentage swings even when broader equity indices are comparatively quiet.
Shares have been volatile over the past month, trading well above their 52-week low as financing announcements and peer-reviewed clinical publications reshaped the investment narrative. The two-day climb pushed the stock through recent short-term resistance levels, reinforcing a technical breakout that can attract additional momentum-driven buying.
What Comes Next for PDSB
Investors will be watching closely for confirmation that the milestone closing conditions are met, specifically the submission of the PDS0301 Phase 3 protocol to the FDA. Additional data readouts from ongoing National Cancer Institute-led trials, further details on the potential PDS0101 licensing discussions with NantWorks, and the company's next quarterly report will all shape sentiment.
At the same time, the financing carries meaningful dilution for existing shareholders, and the company remains pre-revenue with ongoing cash needs. Micro-cap biotech stocks can reverse quickly, and the sustainability of the move will depend on continued clinical execution and successful capital formation. As with any clinical-stage developer, the path forward hinges on trial results and regulatory milestones rather than near-term profitability.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to compare automated approaches across different market environments. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PDSB turns positive, indicating new upward trend
PDSB saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 70 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 67 cases where PDSB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +42.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 85 of 107 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for PDSB moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 20 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PDSB broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-30.773) is normal, around the industry mean (3.151). P/E Ratio (-2.375) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PDSB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Percentage and What Kind of Bonds Should I Have in My Portfolio?
What are the Tax Implications of Owning Bonds?
How Do Short Positions Work? What is the Bearish Side of Trading.
What does the term "surplus" mean, and what are its implications, reasons, and outcomes?
Week (January 20 - 24) in Review: Financial Leaders
General Information
a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers
Industry Biotechnology
Advertisement